Syndrome of Inappropriate Antidiuretic Hormone Secretion
📧 Sign up to get email alerts when something new happens for Syndrome of Inappropriate Antidiuretic Hormone Secretion.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-01-09EMA Authorised: Tolvaptan Accord (tolvaptan) — Accord Healthcare S.L.U.
The EMA authorised Tolvaptan Accord for the treatment of Syndrome of inappropriate antidiuretic hormone secretion (SIADH); Accord Healthcare…
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia [Phase 4]
Phase 4 clinical trial evaluating empagliflozin for euvolemic and hypervolemic hyponatremia (including SIADH); recruitment is ongoing at Uni…
-
CLINICAL_TRIALS research · 2025-07-10Clinical Trial Update: Protein Supplementation in Hyponatremia Due to the Syndrome of Inappropriate Antidiuresis [NA]
A clinical trial evaluating protein supplementation as a treatment for hyponatremia caused by the syndrome of inappropriate antidiuresis is …
-
CLINICAL_TRIALS research · 2025-04-16Clinical Trial Update: Urea Therapy for Hyponatremia in Subarachnoid Hemorrhage [NA]
This clinical trial is evaluating urea therapy to treat hyponatremia in patients with subarachnoid hemorrhage; the study is currently active…
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIAD [NA]
A completed clinical trial evaluating intravenous [Pyr1]Apelin-13 in healthy volunteers with artificially induced SIAD, focusing on effects …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-03-28Clinical Trial Update: Asymptomatic Bacteriuria, Hyponatremia and Geri-atric Syndrome [NA]
This is a completed clinical trial update from Universitair Ziekenhuis Brussel examining asymptomatic bacteriuria in the context of hyponatr…
-
EMA approval · 2025-03-26EMA Authorised: Samsca (tolvaptan) — Otsuka Pharmaceutical Netherlands B.V.
EMA authorised Samsca (tolvaptan) for the treatment of syndrome of inappropriate antidiuretic hormone secretion (SIADH), with Otsuka Pharmac…
-
CLINICAL_TRIALS trial_result · 2025-03-24Clinical Trial Update: Samsca Post-marketing General Drug Use-results Survey in Patients with Hyponatremia in SIADH
This clinical trial update discusses a post-marketing general drug use-results survey evaluating tolvaptan (Samsca) for hyponatremia associa…
-
CLINICAL_TRIALS trial_result · 2024-05-20Clinical Trial Update: Urea for Chronic Hyponatremia [Phase 2]
Phase 2 trial evaluating urea for chronic hyponatremia was terminated. Results were posted on 2024-05-20.
-
FDA approval · 2022-11-08FDA Approved: TOLVAPTAN — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for tolvaptan by Apotex Corp., indicating a regulatory update to the generic product's approval (suc…
-
FDA approval · 2022-09-06FDA Approved: TOLVAPTAN — Original Application (Ascend Laboratories, LLC)
FDA approved a generic version of tolvaptan under an Original Application (ANDA) filed by Ascend Laboratories, LLC.
-
FDA approval · 2022-02-15FDA Approved: TOLVAPTAN — Original Application (Endo USA, Inc.)
FDA approved Endo USA, Inc.'s original application for tolvaptan, a vasopressin V2 receptor antagonist, for the treatment of hyponatremia. T…
-
FDA approval · 2021-07-16FDA Approved: TOLVAPTAN — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' tolvaptan via an original (ANDA) application, indicating a generic tolvaptan product is approved.
-
FDA approval · 2021-04-22FDA Approved: SAMSCA — Supplemental Application (Otsuka America Pharmaceutical, Inc.)
FDA approved a supplemental application for Samsca (tolvaptan) from Otsuka America Pharmaceutical, Inc.
-
CLINICAL_TRIALS trial_result · 2020-11-02Clinical Trial Update: A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH [Phase 3]
Phase 3 multicenter trial evaluating tolvaptan for hyponatremia due to SIADH; study completed with results posted.
-
FDA approval · 2020-05-19FDA Approved: TOLVAPTAN — Original Application (Ascend Laboratories, LLC)
FDA approved Ascend Laboratories LLC's original ANDA for tolvaptan, a vasopressin V2 receptor antagonist, as a generic option for treating h…
-
CLINICAL_TRIALS research · 2019-06-13Clinical Trial Update: Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study [Phase 2, Phase 3]
A clinical trial update investigating the effects of the SGLT2 inhibitor empagliflozin in patients with SIADH (SAND study).
-
CLINICAL_TRIALS withdrawal · 2019-02-06Clinical Trial Update: Fractional Urate Excretion in Nonedematous Hyponatremia [NA]
A clinical trial evaluating fractional urate excretion in nonedematous hyponatremia was withdrawn. The study involved cerebral hyponatremia …
-
FDA approval · 2018-04-23FDA Approved: SAMSCA — Supplemental Application (Otsuka America Pharmaceutical, Inc.)
FDA approved a supplemental application for Samsca (tolvaptan) from Otsuka America Pharmaceutical.
-
CLINICAL_TRIALS trial_result · 2018-04-04Clinical Trial Update: An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy
An observational study conducted in Italy assessed outcomes for cancer patients treated for moderate to severe hyponatremia (often due to SI…
-
CLINICAL_TRIALS trial_result · 2018-02-05Clinical Trial Update: An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH
An observational real-world study evaluated outcomes in patients treated with tolvaptan for hyponatremia due to SIADH, with results posted i…
-
FDA approval · 2017-06-01FDA Approved: SAMSCA — Supplemental Application (Otsuka America Pharmaceutical, Inc.)
FDA approved a supplemental application for SAMSCA (tolvaptan) from Otsuka America Pharmaceutical, Inc., likely updating labeling or expandi…
-
CLINICAL_TRIALS trial_result · 2016-08-10Clinical Trial Update: Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study [Phase 2, Phase 3]
A completed Phase 2/3 clinical trial (the DIVE study) evaluated the effects of empagliflozin, an SGLT2 inhibitor, in healthy volunteers with…
-
CLINICAL_TRIALS trial_result · 2016-05-26Clinical Trial Update: A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia [Phase 3]
A Phase III study evaluating satavaptan versus placebo in patients with dilutional hyponatremia was terminated.
-
CLINICAL_TRIALS trial_result · 2016-05-16Clinical Trial Update: A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) [Phase 1, Phase 2]
A pharmacokinetic study evaluating three Tolvaptan dose levels in patients with SIADH was completed (Phase 1/2) with results posted.